What is Curis?
Curis, Inc. is a biotechnology company dedicated to the discovery and development of novel drug candidates for the treatment of human cancers. Headquartered in Lexington, the company's pipeline includes promising compounds such as CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which has advanced to Phase II clinical trials for certain lymphomas. Curis is also developing other small molecule drug candidates, including CA-170 and CA-4948, targeting various solid tumors and hematologic cancers. The company has established strategic collaborations with entities like Aurigene Discovery Technologies Limited and F. Hoffmann-La Roche Ltd. to accelerate the development and commercialization of its therapeutic agents.
How much funding has Curis raised?
Curis has raised a total of $153.3M across 6 funding rounds:
Corporate Investment
$8M
Debt
$30M
Stock Offering
$64.7M
Share Placement
$30M
Debt
$350K
Private Equity
$20.2M
Corporate Investment (2010): $8M with participation from Debiopharm
Debt (2012): $30M led by Pharmakon Advisors
Stock Issuance/Offering (2015): $64.7M supported by Undisclosed
Share Placement (2020): $30M featuring Aspire Capital Limited
Debt (2020): $350K backed by PPP
Private Equity (2026): $20.2M with participation from Nantahala Capital Management and Stonepine Capital Management
Key Investors in Curis
Pharmakon Advisors
Pharmakon Advisors, operating through biopharmafunds.com, is an entity likely specializing in providing capital and strategic guidance to biotechnology and pharmaceutical companies. Their involvement suggests a focus on the life sciences sector, potentially offering debt financing or equity investments to support drug development and commercialization efforts.
Nantahala Capital Management
Nantahala Capital Management is an investment firm founded in 2004, specializing in micro-cap stocks across various sectors with a multi-year investment horizon. The firm focuses on maximizing risk-adjusted returns and alpha generation through a diversified portfolio of long and short investment ideas, maintaining low or no equity market exposure.
Stonepine Capital Management
Stonepine Capital Management is an investment management company focused on the life sciences sector. The firm specializes in private investments in biotechnology companies, offering advisory and operational expertise to its clients, particularly in commercial-stage companies.
What's next for Curis?
With the infusion of $20.2M in its latest strategic investment, Curis is poised to accelerate its clinical development programs and expand its research into new therapeutic areas. The company's focus on immuno-oncology and precision oncology aligns with current industry trends, suggesting a strategic direction aimed at addressing unmet medical needs in cancer treatment. The enterprise-level funding indicates a mature stage of development, likely Series B or beyond, enabling Curis to pursue ambitious growth strategies and potentially bring its innovative therapies closer to market. Future endeavors will likely involve advancing existing clinical trials, exploring new drug combinations, and potentially seeking further strategic partnerships or regulatory approvals.
See full Curis company page
